Delta-Fly Pharma Updates on DFP-10917 Clinical Trials

MT Newswires Live

Nov 06, 2025

Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.

Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.

A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.

In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581057432"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581057432\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581057432?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581057432","market":"sh","top_or_hot":-1,"title":"Delta-Fly Pharma Updates on DFP-10917 Clinical Trials","media":"MT Newswires Live","content":"<html><body><p> Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.</p><p>Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.</p><p>A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.</p><p>In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Delta-Fly Pharma Updates on DFP-10917 Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDelta-Fly Pharma Updates on DFP-10917 Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-06 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.</p><p>Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.</p><p>A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.</p><p>In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFP","symbol_name":"Flaherty & Crumrine Dynamic","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2581057432","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581057432","pubTimestamp":1762421215,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Delta-Fly Pharma  said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFP":"Flaherty & Crumrine Dynamic"},"translate_title":"Delta-Fly Pharma更新DFP-10917临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFP":1.5},"content_text":"Delta-Fly Pharma (TYO:4598) said data cleaning for the interim analysis of its Phase 3 U.S. trial of DFP-10917 monotherapy for end-stage acute myeloid leukemia is taking longer than planned, according to a Thursday filing on the Tokyo Stock Exchange.Efficacy data from trial sites and bone marrow analysis at the MD Anderson Cancer Center are now available, and the company plans to submit results to the Data Safety Management Board once analysis is complete.A Phase 1/2 study of DFP-10917 combined with venetoclax is progressing and expected to complete patient enrollment soon, with efficacy and safety evaluations by a monitoring committee to follow. Delta-Fly said it may collaborate with a global pharmaceutical partner for Phase 3 studies.In the U.S., an expanded Phase 1 trial of DFP-14927, a drug delivery system for DFP-10917, showed improved disease control but no tumor shrinkage in colorectal cancer patients. The company will continue testing in pancreatic cancer.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}